# Eze/Simva Switch Study in Diabetics (0653A-807)

> **NCT00541697** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 648 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks
- **DRUG:** Comparator: atorvastatin / Duration of Treatment: 6 Weeks

## Key facts

- **NCT ID:** NCT00541697
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01-19
- **Primary completion:** 2005-09-28
- **Final completion:** 2005-10-14
- **Target enrollment:** 648 (ACTUAL)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00541697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00541697, "Eze/Simva Switch Study in Diabetics (0653A-807)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00541697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*